nach oben

Erschienen in:

09.03.2020 | Topic Review

Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis

verfasst von: Lina Marenco-Hillembrand, Olindi Wijesekera, Paola Suarez-Meade, David Mampre, Christina Jackson, Jennifer Peterson, Daniel Trifiletti, Julie Hammack, Kyle Ortiz, Elizabeth Lesser, Matthew Spiegel, Calder Prevatt, Maria Hawayek, Alfredo Quinones-Hinojosa, Kaisorn L. Chaichana

Erschienen in: Journal of Neuro-Oncology | Ausgabe 2/2020

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Despite aggressive treatment with chemoradiotherapy and maximum surgical resection, survival in patients with glioblastoma (GBM) remains poor. Ongoing efforts are aiming to prolong the lifespan of these patients; however, disparities exist in reported survival values with lack of clear evidence that objectively examines GBM survival trends. We aim to describe the current status and advances in the survival of patients with GBM, by analyzing median overall survival through time and between treatment modalities.

Methods

A systematic review was conducted according to PRISMA guidelines to identify articles of newly diagnosed glioblastoma from 1978 to 2018. Full-text glioblastoma papers with human subjects, ≥ 18 years old, and n ≥ 25, were included for evaluation.

Results

The central tendency of median overall survival (MOS) was 13.5 months (2.3–29.6) and cumulative 5-year survival was 5.8% (0.01%–29.1%), with a significant difference in survival between studies that predate versus postdate the implementation of temozolomide and radiation, [12.5 (2.3–28) vs 15.6 (3.8–29.6) months, P < 0.001]. In clinical trials, bevacizumab [18.2 (10.6–23.0) months], tumor treating fields (TTF) [20.7 (20.5–20.9) months], and vaccines [19.2 (15.3–26.0) months] reported the highest central measure of median survival.

Conclusion

Coadministration with radiotherapy and temozolomide provided a statistically significant increase in survival for patients suffering from glioblastoma. However, the natural history for GBM remains poor. Therapies including TTF pooled values of MOS and provide means of prolonging the survival of GBM patients.

Nur mit Berechtigung zugänglich

Ostrom QT, Gittleman H, Liao P, Vecchione-Koval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS (2017) CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro Oncol 19:v1–v88. https://doi.org/10.1093/neuonc/nox158 CrossRefPubMedPubMedCentral

Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W, Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A, Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP (2017) Short-course radiation plus temozolomide in elderly patients with glioblastoma. N Engl J Med 376:1027–1037. https://doi.org/10.1056/NEJMoa1611977 CrossRefPubMed

Raysi Dehcordi S, De Paulis D, Marzi S, Ricci A, Cimini A, Cifone MG, Galzio RJ (2012) Survival prognostic factors in patients with glioblastoma: our experience. J Neurosurg Sci 56:239–245PubMed

Roberts PS, Nuno M, Sherman D, Asher A, Wertheimer J, Riggs RV, Patil CG (2014) The impact of inpatient rehabilitation on function and survival of newly diagnosed patients with glioblastoma. Pm r 6:514–521. https://doi.org/10.1016/j.pmrj.2013.12.007 CrossRefPubMed

Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, Quinones-Hinojosa A (2011) Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. J Neurosurg 114:587–594. https://doi.org/10.3171/2010.8.Jns1081 CrossRefPubMed

Chaichana KL, Halthore AN, Parker SL, Olivi A, Weingart JD, Brem H, Quinones-Hinojosa A (2011) Factors involved in maintaining prolonged functional independence following supratentorial glioblastoma resection. J Neurosurg 114:604–612. https://doi.org/10.3171/2010.4.Jns091340 CrossRefPubMed

Hulshof MC, Koot RW, Schimmel EC, Dekker F, Bosch DA, Gonzalez Gonzalez D (2001) Prognostic factors in glioblastoma multiforme. 10 years experience of a single institution. Strahlenther Onkol 177:283–290CrossRefPubMed

Lukas RV, Wainwright DA, Ladomersky E, Sachdev S, Sonabend AM, Stupp R (2019) Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park) 33:91–100

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996. https://doi.org/10.1056/NEJMoa043330 CrossRefPubMed

10.

Cantrell JN, Waddle MR, Rotman M, Peterson JL, Ruiz-Garcia H, Heckman MG, Quinones-Hinojosa A, Rosenfeld SS, Brown PD, Trifiletti DM (2019) Progress toward long-term survivors of glioblastoma. Mayo Clin Proc 94:1278–1286. https://doi.org/10.1016/j.mayocp.2018.11.031 CrossRefPubMed

11.

Tykocki T, Eltayeb M (2018) Ten-year survival in glioblastoma A systematic review. J Clin Neurosci 54:7–13. https://doi.org/10.1016/j.jocn.2018.05.002 CrossRefPubMed

12.

Chaudhry NS, Shah AH, Ferraro N, Snelling BM, Bregy A, Madhavan K, Komotar RJ (2013) Predictors of long-term survival in patients with glioblastoma multiforme: advancements from the last quarter century. Cancer Invest 31:287–308. https://doi.org/10.3109/07357907.2013.789899 CrossRefPubMed

13.

Thomas AA, Brennan CW, DeAngelis LM, Omuro AM (2014) Emerging therapies for glioblastoma. JAMA Neurol 71:1437–1444. https://doi.org/10.1001/jamaneurol.2014.1701 CrossRefPubMed

14.

Jain KK (2018) A critical overview of targeted therapies for glioblastoma. Front Oncol 8:419. https://doi.org/10.3389/fonc.2018.00419 CrossRefPubMedPubMedCentral

15.

Lim M, Xia Y, Bettegowda C, Weller M (2018) Current state of immunotherapy for glioblastoma. Nat Rev Clin Oncol 15:422–442. https://doi.org/10.1038/s41571-018-0003-5 CrossRefPubMed

16.

Ramos AD, Magge RS, Ramakrishna R (2018) Molecular pathogenesis and emerging treatment for glioblastoma. World Neurosurg 116:495–504. https://doi.org/10.1016/j.wneu.2018.04.021 CrossRefPubMed

17.

Chaichana K, Parker S, Olivi A, Quinones-Hinojosa A (2010) A proposed classification system that projects outcomes based on preoperative variables for adult patients with glioblastoma multiforme. J Neurosurg 112:997–1004. https://doi.org/10.3171/2009.9.Jns09805 CrossRefPubMed

18.

Chaichana KL, Garzon-Muvdi T, Parker S, Weingart JD, Olivi A, Bennett R, Brem H, Quinones-Hinojosa A (2011) Supratentorial glioblastoma multiforme: the role of surgical resection versus biopsy among older patients. Ann Surg Oncol 18:239–245. https://doi.org/10.1245/s10434-010-1242-6 CrossRefPubMed

19.

Chaichana KL, McGirt MJ, Frazier J, Attenello F, Guerrero-Cazares H, Quinones-Hinojosa A (2008) Relationship of glioblastoma multiforme to the lateral ventricles predicts survival following tumor resection. J Neurooncol 89:219–224. https://doi.org/10.1007/s11060-008-9609-2 CrossRefPubMed

20.

Oxford Centre for evidence-based medicine: levels of evidence (March 2009). https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009/

21.

Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di Meco F, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z (2017) Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma: a randomized clinical trial. JAMA 318:2306–2316. https://doi.org/10.1001/jama.2017.18718 CrossRefPubMedPubMedCentral

22.

Stupp R, Taillibert S, Kanner AA, Kesari S, Steinberg DM, Toms SA, Taylor LP, Lieberman F, Silvani A, Fink KL, Barnett GH, Zhu JJ, Henson JW, Engelhard HH, Chen TC, Tran DD, Sroubek J, Tran ND, Hottinger AF, Landolfi J, Desai R, Caroli M, Kew Y, Honnorat J, Idbaih A, Kirson ED, Weinberg U, Palti Y, Hegi ME, Ram Z (2015) Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA 314:2535–2543. https://doi.org/10.1001/jama.2015.16669 CrossRefPubMed

23.

Narayana A, Gruber D, Kunnakkat S, Golfinos JG, Parker E, Raza S, Zagzag D, Eagan P, Gruber ML (2012) A clinical trial of bevacizumab, temozolomide, and radiation for newly diagnosed glioblastoma. J Neurosurg 116:341–345. https://doi.org/10.3171/2011.9.Jns11656 CrossRefPubMed

24.

Vredenburgh JJ, Desjardins A, Reardon DA, Peters KB, Herndon JE 2nd, Marcello J, Kirkpatrick JP, Sampson JH, Bailey L, Threatt S, Friedman AH, Bigner DD, Friedman HS (2011) The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma. Clin Cancer Res 17:4119–4124. https://doi.org/10.1158/1078-0432.Ccr-11-0120 CrossRefPubMedPubMedCentral

25.

Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ Jr, Mehta MP (2014) A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 370:699–708. https://doi.org/10.1056/NEJMoa1308573 CrossRefPubMedPubMedCentral

26.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T (2014) Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 370:709–722. https://doi.org/10.1056/NEJMoa1308345 CrossRefPubMed

27.

Snelling L, Miyamoto CT, Bender H, Brady LW, Steplewski Z, Class R, Emrich J, Rackover MA (1995) Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14:111–114. https://doi.org/10.1089/hyb.1995.14.111 CrossRefPubMed

28.

Wang Y, Pan L, Sheng XF, Chen S, Dai JZ (2016) Nimotuzumab, a humanized monoclonal antibody specific for the EGFR, in combination with temozolomide and radiation therapy for newly diagnosed glioblastoma multiforme: First results in Chinese patients. Asia Pac J Clin Oncol 12:e23–29. https://doi.org/10.1111/ajco.12166 CrossRefPubMed

29.

Solomon MT, Selva JC, Figueredo J, Vaquer J, Toledo C, Quintanal N, Salva S, Domingez R, Alert J, Marinello JJ, Catala M, Griego MG, Martell JA, Luaces PL, Ballesteros J, Castro N, Bach F, Crombet T (2013) Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial. BMC Cancer 13:299. https://doi.org/10.1186/1471-2407-13-299 CrossRefPubMedPubMedCentral

30.

Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, Mrugala MM, Jensen R, Baehring JM, Sloan A, Archer GE, Bigner DD, Cruickshank S, Green JA, Keler T, Davis TA, Heimberger AB, Sampson JH (2015) A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol 17:854–861. https://doi.org/10.1093/neuonc/nou348 CrossRefPubMedPubMedCentral

31.

Weller M, Butowski N, Tran DD, Recht LD, Lim M, Hirte H, Ashby L, Mechtler L, Goldlust SA, Iwamoto F, Drappatz J, O'Rourke DM, Wong M, Hamilton MG, Finocchiaro G, Perry J, Wick W, Green J, He Y, Turner CD, Yellin MJ, Keler T, Davis TA, Stupp R, Sampson JH (2017) Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial. Lancet Oncol 18:1373–1385. https://doi.org/10.1016/s1470-2045(17)30517-x CrossRefPubMed

32.

Ardon H, Van Gool SW, Verschuere T, Maes W, Fieuws S, Sciot R, Wilms G, Demaerel P, Goffin J, Van Calenbergh F, Menten J, Clement P, Debiec-Rychter M, De Vleeschouwer S (2012) Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial. Cancer Immunol Immunother 61:2033–2044. https://doi.org/10.1007/s00262-012-1261-1 CrossRefPubMed

33.

Rampling R, Peoples S, Mulholland PJ, James A, Al-Salihi O, Twelves CJ, McBain C, Jefferies S, Jackson A, Stewart W, Lindner J, Kutscher S, Hilf N, McGuigan L, Peters J, Hill K, Schoor O, Singh-Jasuja H, Halford SE, Ritchie JW (2016) A cancer research UK first time in human phase I trial of IMA950 (novel multipeptide therapeutic vaccine) in patients with newly diagnosed glioblastoma. Clin Cancer Res 22:4776–4785. https://doi.org/10.1158/1078-0432.Ccr-16-0506 CrossRefPubMedPubMedCentral

34.

Dillman RO, Duma CM, Ellis RA, Cornforth AN, Schiltz PM, Sharp SL, DePriest MC (2009) Intralesional lymphokine-activated killer cells as adjuvant therapy for primary glioblastoma. J Immunother 32:914–919. https://doi.org/10.1097/CJI.0b013e3181b2910f CrossRefPubMed

35.

Westphal M, Yla-Herttuala S, Martin J, Warnke P, Menei P, Eckland D, Kinley J, Kay R, Ram Z (2013) Adenovirus-mediated gene therapy with sitimagene ceradenovec followed by intravenous ganciclovir for patients with operable high-grade glioma (ASPECT): a randomised, open-label, phase 3 trial. Lancet Oncol 14:823–833. https://doi.org/10.1016/s1470-2045(13)70274-2 CrossRefPubMed

36.

Ursu R, Carpentier A, Metellus P, Lubrano V, Laigle-Donadey F, Capelle L, Guyotat J, Langlois O, Bauchet L, Desseaux K, Tibi A, Chinot O, Lambert J, Carpentier AF (2017) Intracerebral injection of CpG oligonucleotide for patients with de novo glioblastoma-A phase II multicentric, randomised study. Eur J Cancer 73:30–37. https://doi.org/10.1016/j.ejca.2016.12.003 CrossRefPubMed

37.

Noch EK, Ramakrishna R, Magge R (2018) Challenges in the Treatment of Glioblastoma: Multisystem Mechanisms of Therapeutic Resistance. World Neurosurg 116:505–517. https://doi.org/10.1016/j.wneu.2018.04.022 CrossRefPubMed

38.

Braun K, Ahluwalia MS (2017) Treatment of Glioblastoma in Older Adults. Curr Oncol Rep 19:81. https://doi.org/10.1007/s11912-017-0644-z CrossRefPubMed

39.

Shergalis A, Bankhead A 3rd, Luesakul U, Muangsin N, Neamati N (2018) Current challenges and opportunities in treating glioblastoma. Pharmacol Rev 70:412–445. https://doi.org/10.1124/pr.117.014944 CrossRefPubMedPubMedCentral

40.

Aldape K, Brindle KM, Chesler L, Chopra R, Gajjar A, Gilbert MR, Gottardo N, Gutmann DH, Hargrave D, Holland EC, Jones DTW, Joyce JA, Kearns P, Kieran MW, Mellinghoff IK, Merchant M, Pfister SM, Pollard SM, Ramaswamy V, Rich JN, Robinson GW, Rowitch DH, Sampson JH, Taylor MD, Workman P, Gilbertson RJ (2019) Challenges to curing primary brain tumours. Nat Rev Clin Oncol 16:509–520. https://doi.org/10.1038/s41571-019-0177-5 CrossRefPubMedPubMedCentral

41.

Yang W, Xu T, Garzon-Muvdi T, Jiang C, Huang J, Chaichana KL (2018) Survival of ventricular and periventricular high-grade gliomas: a surveillance, epidemiology, and end results program-based study. World Neurosurg 111:e323–e334. https://doi.org/10.1016/j.wneu.2017.12.052 CrossRefPubMed

42.

Woo P, Ho J, Lam S, Ma E, Chan D, Wong WK, Mak C, Lee M, Wong ST, Chan KY, Poon WS (2018) A comparative analysis of the usefulness of survival prediction models for patients with glioblastoma in the temozolomide era: the importance of methylguanine methyltransferase promoter methylation, extent of resection, and subventricular zone location. World Neurosurg 115:e375–e385. https://doi.org/10.1016/j.wneu.2018.04.059 CrossRefPubMed

43.

Fatehi M, Hunt C, Ma R, Toyota BD (2018) Persistent disparities in survival for patients with glioblastoma. World Neurosurg 120:e511–e516. https://doi.org/10.1016/j.wneu.2018.08.114 CrossRefPubMed

44.

Shah BK, Bista A, Sharma S (2016) Survival trends in elderly patients with glioblastoma in the United States: a population-based study. Anticancer Res 36:4883–4886. https://doi.org/10.21873/anticanres.11052 CrossRefPubMed

45.

Witthayanuwat S, Pesee M, Supaadirek C, Supakalin N, Thamronganantasakul K, Krusun S (2018) Survival analysis of glioblastoma multiforme. Asian Pac J Cancer Prev 19:2613–2617. https://doi.org/10.22034/apjcp.2018.19.9.2613 CrossRefPubMedPubMedCentral

46.

Teo M, Martin S, Owusu-Agyemang K, Nowicki S, Clark B, Mackinnon M, Stewart W, Paul J, St George J (2014) A survival analysis of GBM patients in the West of Scotland pre- and post-introduction of the Stupp regime. Br J Neurosurg 28:351–355. https://doi.org/10.3109/02688697.2013.847170 CrossRefPubMed

47.

Balana C, De Las PR, Sepulveda JM, Gil-Gil MJ, Luque R, Gallego O, Carrato C, Sanz C, Reynes G, Herrero A, Ramirez JL, Perez-Segura P, Berrocal A, Vieitez JM, Garcia A, Vazquez-Estevez S, Peralta S, Fernandez I, Henriquez I, Martinez-Garcia M, De la Cruz JJ, Capellades J, Giner P, Villa S (2016) Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial. J Neurooncol 127:569–579. https://doi.org/10.1007/s11060-016-2065-5 CrossRefPubMed

48.

Hofland KF, Hansen S, Sorensen M, Engelholm S, Schultz HP, Muhic A, Grunnet K, Ask A, Costa JC, Kristiansen C, Thomsen C, Poulsen HS, Lassen U (2014) Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: a randomized phase II study. Acta Oncol 53:939–944. https://doi.org/10.3109/0284186x.2013.879607 CrossRefPubMed

49.

Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, Friedman HS, Gilbert MR, Herndon JE 2nd, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD (2010) Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol 28:4722–4729. https://doi.org/10.1200/jco.2010.28.6963 CrossRefPubMedPubMedCentral

50.

Rick J, Chandra A, Aghi MK (2018) Tumor treating fields: a new approach to glioblastoma therapy. J Neurooncol 137:447–453. https://doi.org/10.1007/s11060-018-2768-x CrossRefPubMed

51.

Kirson ED, Dbaly V, Tovarys F, Vymazal J, Soustiel JF, Itzhaki A, Mordechovich D, Steinberg-Shapira S, Gurvich Z, Schneiderman R, Wasserman Y, Salzberg M, Ryffel B, Goldsher D, Dekel E, Palti Y (2007) Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci USA 104:10152–10157. https://doi.org/10.1073/pnas.0702916104 CrossRefPubMedPubMedCentral

52.

Stupp R, Wong ET, Kanner AA, Steinberg D, Engelhard H, Heidecke V, Kirson ED, Taillibert S, Liebermann F, Dbaly V, Ram Z, Villano JL, Rainov N, Weinberg U, Schiff D, Kunschner L, Raizer J, Honnorat J, Sloan A, Malkin M, Landolfi JC, Payer F, Mehdorn M, Weil RJ, Pannullo SC, Westphal M, Smrcka M, Chin L, Kostron H, Hofer S, Bruce J, Cosgrove R, Paleologous N, Palti Y, Gutin PH (2012) NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer 48:2192–2202. https://doi.org/10.1016/j.ejca.2012.04.011 CrossRefPubMed

53.

Thakkar JP, Dolecek TA, Horbinski C, Ostrom QT, Lightner DD, Barnholtz-Sloan JS, Villano JL (2014) Epidemiologic and molecular prognostic review of glioblastoma. Cancer Epidemiol Biomarkers Prev 23:1985–1996. https://doi.org/10.1158/1055-9965.Epi-14-0275 CrossRefPubMedPubMedCentral

Titel: Trends in glioblastoma: outcomes over time and type of intervention: a systematic evidence based analysis
verfasst von: Lina Marenco-Hillembrand
Olindi Wijesekera
Paola Suarez-Meade
David Mampre
Christina Jackson
Jennifer Peterson
Daniel Trifiletti
Julie Hammack
Kyle Ortiz
Elizabeth Lesser
Matthew Spiegel
Calder Prevatt
Maria Hawayek
Alfredo Quinones-Hinojosa
Kaisorn L. Chaichana
Publikationsdatum: 09.03.2020
Verlag: Springer US
Erschienen in: Journal of Neuro-Oncology / Ausgabe 2/2020
Print ISSN: 0167-594X
Elektronische ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-020-03451-6

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Introduction

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2020

Extent of re-excision, sequence/timing of salvage re-irradiation, and disease-free interval impact upon clinical outcomes in recurrent/progressive ependymoma

Clinical presentation of young people (10–24 years old) with brain tumors: results from the international MOBI-Kids study

A genome-wide association study on medulloblastoma

T-Cell based therapies for overcoming neuroanatomical and immunosuppressive challenges within the glioma microenvironment

Super selective intra-arterial cerebral infusion of modern chemotherapeutics after blood–brain barrier disruption: where are we now, and where we are going